Table 5. Dose reductions and treatment interruption or discontinuation.
| Cohort 1: Capecitabine | Cohort 2: 5-FU | |||||||
|---|---|---|---|---|---|---|---|---|
| Overall (251) | PPI (51) | Non-PPI (200) | p value | Overall (196) | PPI (52) | Non-PPI (144) | p value | |
| Dose reduction No Yes Missing |
170 (67.7%) 70 (27.9%) 11 (4.4%) |
36 (73.5%) 13 (26.5%) 2 |
134 (70.2%) 57 (29.8%) 9 |
0.73 |
162 (82.7%) 34 (17.6%) 0 |
43 (82.7%) 9 (17.3%) 0 |
119 (82.6%) 25 (17.4%) 0 |
1.00 |
| Pause for toxicitya No Yes Missing |
229 (91.2%) 22 (8.8%) 9 (3.6%) |
46 (93.9%) 3 (6.1%) 2 |
173 (89.6%) 20 (10.4%) 7 |
0.58 |
187 (95.4%) 9 (4.6%) 0 |
51 (98.1%) 1 (1.9%) 0 |
136 (94.4%) 8 (5.6%) 0 |
0.45 |
a
Temporary pause or definitive discontinuation
PPI: proton-pump inhibitors